<h2 dir="ltr">Respiratory Syncytial Virus (RSV)</h2>
Respiratory Syncytial Virus (RSV) is a common, highly contagious viral infection affecting the respiratory tract. It is a leading cause of upper and lower respiratory illnesses, particularly in infants, young children, and older adults. Early identification and preventive strategies are critical to reduce hospitalizations and severe outcomes.
<h2 dir="ltr">Respiratory Syncytial Virus Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Incident Cases of RSV 
</li>
<li dir="ltr" aria-level="1">
Age-Specific Incident Cases of RSV 
</li>
<li dir="ltr" aria-level="1">
Severity-Specific RSV Cases (Children and Adults) 
</li>
<li dir="ltr" aria-level="1">
Total Population Eligible for RSV Vaccination 
</li>
<li dir="ltr" aria-level="1">
Age-Group&ndash;Specific RSV Cases 
</li>
</ul>
<h2 dir="ltr"><a href="https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-epidemiology-forecast">Respiratory Syncytial Virus Epidemiology</a></h2>
<ul>
<li dir="ltr" aria-level="1">
The total incident cases of RSV across the 7 Major Markets were approximately 4.2 million in 2023. 
</li>
<li dir="ltr" aria-level="1">
RSV shows a high disease burden in children below 5 years and adults above 65 years. 
</li>
<li dir="ltr" aria-level="1">
In the United States, severity distribution among children was dominated by mild cases (70%), followed by moderate (27%) and severe cases (3%). 
</li>
<li dir="ltr" aria-level="1">
Among adults in the US, moderate cases (64%) were most prevalent, followed by severe (19%) and mild cases (17%). 
</li>
<li dir="ltr" aria-level="1">
Age-group analysis across the 7MM indicates that 49% of cases occur in children below 5 years, 15% in individuals aged 5&ndash;64, and 37% in adults above 65 years, highlighting the bimodal risk profile of RSV. 
</li>
</ul>
<h2 dir="ltr">Respiratory Syncytial Virus Market</h2>
<ul>
<li dir="ltr" aria-level="1">
Within the 7 Major Markets (7MM), the United States accounted for nearly 68% of the total RSV market share in 2023. 
</li>
<li dir="ltr" aria-level="1">
The total RSV market size across the 7MM was estimated at approximately USD 7.6 billion in 2023. 
</li>
<li dir="ltr" aria-level="1">
The RSV market is expected to expand significantly during the forecast period (2024&ndash;2034), driven by increasing disease awareness, improved diagnostic rates, and rising adoption of newly approved vaccines. 
</li>
</ul>
<h2 dir="ltr">Respiratory Syncytial Virus Market Drivers</h2>
<ul>
<li dir="ltr" aria-level="1">
Rising vaccination uptake, particularly among infants, pregnant women, and older adults, is a key growth driver of the RSV market. 
</li>
<li dir="ltr" aria-level="1">
Advances in monoclonal antibodies and vaccine technologies, such as extended half-life antibodies, have strengthened preventive strategies and reduced RSV-related hospitalizations. 
</li>
<li dir="ltr" aria-level="1">
Growing awareness of RSV-associated complications in high-risk populations has increased demand for prophylactic and supportive care interventions. 
</li>
</ul>
<h2 dir="ltr">Respiratory Syncytial Virus Market Barriers</h2>
<ul>
<li dir="ltr" aria-level="1">
The need to immunize very young infants, who may exhibit suboptimal immune responses, poses a significant challenge to vaccine development. 
</li>
<li dir="ltr" aria-level="1">
The presence of two antigenically distinct RSV subtypes (A and B) complicates the development of broadly protective vaccines. 
</li>
<li dir="ltr" aria-level="1">
Historical concerns related to vaccine-associated disease enhancement continue to influence regulatory scrutiny and development timelines. 
</li>
<li dir="ltr" aria-level="1">
Despite recent approvals, treatment options remain largely supportive, highlighting persistent unmet needs in antiviral therapy. 
</li>
</ul>
<h2 dir="ltr"><a href="https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight">Emerging Respiratory Syncytial Virus Drugs</a></h2>
<ul>
<li dir="ltr" aria-level="1">
BEYFORTUS&nbsp;
</li>
<li dir="ltr" aria-level="1">
AREXVY 
</li>
<li dir="ltr" aria-level="1">
ABRYSVO 
</li>
</ul>
Key Respiratory Syncytial Virus Companies
<ul>
<li dir="ltr" aria-level="1">
AstraZeneca 
</li>
<li dir="ltr" aria-level="1">
GSK
</li>
<li dir="ltr" aria-level="1">
Pfizer
</li>
</ul>
&nbsp;

Respiratory Syncytial Virus Market

Respiratory Syncytial Virus Market Infographics

Respiratory Syncytial Virus Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape